Jay Venkatesan, MD, MBA, President and CEO
Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures. Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners). He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.
Itzhak Goldberg, MD., FACR, Executive Chairman, Board Chairman, and CSO
Dr. Goldberg was formerly a faculty member at Harvard Medical School, Boston, MA, Radiation Oncologist-in-Chief for the North Shore-LIJ (Northwell) Health System, , NY, and Professor at the Albert Einstein College of Medicine, Bronx, NY. Dr. Goldberg has made seminal contributions in the field of Tyrosine Kinase Receptors and Hepatocyte Growth Factor research and has been the driving force within Angion since he started the company. Under Dr. Goldberg’s leadership Angion received continuous non-dilutive NIH, DOD and NSF grants and successfully raised Series A/B funding.
John F. Neylan, M.D. Senior Vice President and Chief Medical Officer
Prior to Angion, Dr. Neylan served as Chief Medical Officer of Keryx, a biopharmaceutical company focused on nephrology. Previously, Dr. Neylan served as Senior Vice President, Clinical Development, at Genzyme Corporation, focusing on specialty metabolic diseases. From 2000-2008, Dr. Neylan served as Vice President, Research and Development for Wyeth Research, overseeing the clinical development of transplantation therapeutics and providing medical affairs support to the transplant franchise.
Prior to joining industry, Dr. Neylan held prestigious positions in academia, including Professor of Medicine at Emory University and Assistant Professor of Medicine at University of California, Davis, serving at both institutions as Medical Director of the respective Renal Transplant Programs, with oversight of the clinical research programs. Dr. Neylan received his BS from Duke University and his MD from Rush Medical School in Chicago. He completed his Internal Medicine residency at Vanderbilt University and fellowships in Nephrology and in Transplantation and Immunogenetics at Brigham and Women’s Hospital, Harvard University. Dr. Neylan has a proven track record for successful INDs, NDA/BLAs, and MAAs involving NCEs, polymers, biologics and RNA-based therapeutics and has authored more than 70 scientific manuscripts and book chapters. He is Past-President of the American Society of Transplantation and past Board Member of the National Kidney Foundation, and a past Industry Representative on the FDA Cardiovascular and Renal Drugs Advisory Committee.
Prakash Narayan, Ph.D., Vice President - Preclinical Research
Dr. Narayan is an expert in models of acute organ injury and fibrosis and is the recipient of multiple NIH, DoD and NSF translational research awards. He is an expert panelist for the European Society of Translational Medicine and a member of the Baltimore PKD Organization. Dr. Narayan received his doctorate from Ohio State University and conducted postdoctoral research at University of Wisconsin-Madison.
Elisha Y. Goldberg, MBA, Director of Business Development
Mr. Goldberg leads business developments efforts for Angion Biomedica. Primary responsibilities include capital raising, strategic partnerships, and licensing agreements. Mr. Goldberg previously founded Broadfire Technologies, a thin client architecture company run out of MIT’s Lab for Computer Science (LCS) under Dr. Michael Dertouzos. He has also worked in equities and investment banking for multiple financial institutions, including Goldman Sachs, in the United States and abroad. Mr. Goldberg received his MBA from Columbia Business School with a concentration in corporate finance in 2005.
Patrick Simms. BSc., Director, Clinical Operations, Regulatory Affairs
Patrick brings more than 23 years of experience in drug development contributing to the marketing of over 30 drug products. Originally a chemist with Boehringer Ingelheim he moved into regulatory affairs and clinical development. In the start-up environments at Mannkind Pharma and Biodel, Patrick managed global clinical trials, lead FDA interactions, and New Drug Application authoring. Mr.Simms studied Biochemistry at Connecticut University.
SCIENTIFIC ADVISORY BOARD
Nezam H. Afdhal, M.D., Harvard Medical School
Dr. Afdhal is Professor of Medicine at Harvard Medical School and Director of Hepatology and the Liver Center at Beth Israel Deaconess Medical Center, MA. An internationally recognized hepatologist, Dr. Afdhal’s clinical expertise focuses on the management of the complications of liver disease, including cirrhosis and portal hypertension and has been clinical investigator on several trials. Dr. Afdhal serves as Chair of Clinical Advisory Board and is a Member of Scientific Advisory Boards at Spring Bank Pharmaceuticals, Inc. and Ligand Pharmaceuticals Inc. Dr. Afdhal has also been a Member of Strategic Advisory Board at Medgenics, Inc. since January 24, 2012. Dr. Afdhal is on the advisory board of the American Liver Foundation and the Massachusetts State Advisory Board for HCV. He has published more than 180 papers in journals such as Gastroenterology, Hepatology, Gut, and Journal of Hepatology, as well as 30 book chapters and two books.
Matthew Cooper, M.D., Georgetown University Medical Center
Dr. Cooper is Professor of Surgery, Director of Kidney and Pancreas Transplantation, Medstar Georgetown Transplant Institute, at Georgetown University Medical Center in Washington, D.C. As director of MedStar Georgetown’s Kidney Transplant Program, Dr. Cooper’s focus is living donation and living donor safety. Dr. Cooper also serves on the board of the United Network for Organ Sharing (UNOS). He was immediate past chair of the Living Donor Committee as well as the National Kidney Foundation. Dr. Cooper is also a member of the National Kidney Foundation's public policy committee, living donor council executive committee and "End the Wait" task force.
Jack A. Elias, M.D., Brown University
Dr. Elias is the Frank L. Day Professor of Biology and Dean of Medicine and Biologic Sciences at Brown University. With a professional career spanning over 30 years, he has made seminal contributions to our understanding of interstitial lung disease. Previously Chair of Medicine at Yale University, Dr. Elias, whose recent honors include election to the Institute of Medicine and the presidency of the Association of American Physicians, has published over 200 original peer-reviewed research papers and has frequently earned funding from industry and private foundations.
Agnes Fogo, M.D., F.A.S.N., Vanderbilt University
Dr. Fogo is the John L. Shapiro Chair of Pathology, Professor of Pathology, Medicine and Pediatrics and Director, Division of Renal Pathology and Electron Microscopy at Vanderbilt University Medical Center. An expert in the area of glomerulosclerosis, Dr. Fogo has published over 280 research articles and reviews and has authored two textbooks of renal pathology. She has served as Pathology Editor for the American Journal of Kidney Disease, Associate Editor for American Journal of Pathology and The Journal of the American Society of Nephrology. She is currently Section Editor for Nephrology Dialysis and Transplantation and Associate Editor for Laboratory Investigation.
Scott L. Friedman, M.D., Mt. Sinai School of Medicine
Dr. Friedman is Chief of Liver Diseases and Dean for Therapeutic Discovery at the Mount Sinai School of Medicine. Having performed pioneering research into the underlying causes of hepatic fibrosis, he is considered an opinion leader in liver diseases. Dr. Friedman is also broadly recognized as a respected clinician, educator, scientist and academic leader. The 2003 International Hans Popper Awardee, Dr. Friedman is a past President of the American Association for the Study of Liver Diseases.
Fred Peter Guengerich, Ph.D., Vanderbilt University
Dr. Guengerich is the Tadashi Inagami Chair in Biochemistry, Professor of Biochemistry and Director of the Center in Molecular Toxicology at Vanderbilt University. He is author or co-author of over 500 peer-reviewed scientific articles, and brings considerable expertise in toxicology, investigating cytochrome P450, DNA damage and carcinogenesis, and drug metabolism. Dr. Guengerich’s group has published three papers in the Journal of Biological Chemistry that have had a major impact on the pharmaceutical industry and the field of biochemical research.
Matthew R. Weir, M.D., University of Maryland School of Medicine
Matthew R. Weir, MD, is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School Of Medicine. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, blood pressure salt sensitivity, biomeasures of cardiovascular disease, and preventing allograft nephropathy in transplant recipients. He has written more than 500 manuscripts and book chapters about these topics.